Tirzepatide (Zepbound) A New Treatment for Obstructive Sleep Apnea and Obesity In December 2024, the FDA approved Tirzepatide (Zepbound) for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity
This once-weekly injectable medication, when combined with lifestyle changes, has shown promising results in promoting weight loss and improving blood sugar management
Impact of delivery mode on infant gut microbiota
In fact, by helping regulate blood sugar and reducing inflammation associated with excess weight, GLP-1 therapy may support overall immune health
It should not be confused with the inflammatory host response seen in dysplastic or malignant melanocytic proliferations (see the following texts)
Among PLS patient families, clinically asymptomatic heterozygous carriers demonstrated DPP1 activity reduced to only 13%47% of controls, suggesting that PLS-like symptoms may only emerge when DPP1 inhibition exceeds 80%90% ( 3.2 Role of NSPs in inflammatory lung diseases In inflammatory lung diseases including NCFBE, COPD, and CF, neutrophil-mediated inflammatory responses constitute the core pathological mechanism ( Shoemark et al
